Cyclerion Therapeutics (CYCN) Gains from Sales and Divestitures (2019 - 2025)
Cyclerion Therapeutics (CYCN) recorded quarterly Gains from Sales and Divestitures of $45072.0 in Q3 2025, up 50.0% quarter-over-quarter from $30048.0 in Q2 2025, and down 20.56% on a YoY basis from $56739.0 in Q3 2024.
Cyclerion Therapeutics (CYCN) Gains from Sales and Divestitures (2019 - 2025) Analysis & Trends
Cyclerion Therapeutics' Gains from Sales and Divestitures history runs 7 years deep, the most recent figure standing at $45072.0 for Q3 2025.
- In Q3 2025, Gains from Sales and Divestitures fell 20.56% year-over-year to $45072.0; the TTM figure through Sep 2025 stood at $45072.0 (down 20.56% YoY), while the FY2024 annual figure was $71763.0, up 30.48% from the prior year.
- Gains from Sales and Divestitures was $45072.0 for Q3 2025 at Cyclerion Therapeutics, up from $30048.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $143774.0 in Q4 2021 to a low of $3375.0 in Q2 2023.
- Historically, Gains from Sales and Divestitures has averaged $49890.1 across 5 years, with a median of $45072.0 in 2025.
- The sharpest annual moves came in 2023 and 2024: Gains from Sales and Divestitures sank 91.49% in 2023, then soared 1136.0% in 2024.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $143774.0 in 2021, then slumped by 62.44% to $53999.0 in 2022, then gained by 1.85% to $55000.0 in 2023, then soared by 30.48% to $71763.0 in 2024, then slumped by 37.19% to $45072.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $45072.0 (Q3 2025), $30048.0 (Q2 2025), and $15024.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Cyclerion Therapeutics | 11.94 Mn | 8.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 45,072.00 |
| Sep 30, 2025 | 45,072.00 |
| Jun 30, 2025 | 30,048.00 |
| Jun 30, 2025 | 30,048.00 |
| Mar 31, 2025 | 15,024.00 |
| Mar 31, 2025 | 15,024.00 |
| Dec 31, 2024 | 71,763.00 |
| Dec 31, 2024 | 71,763.00 |
| Sep 30, 2024 | 56,739.00 |
| Sep 30, 2024 | 56,739.00 |
| Jun 30, 2024 | 41,715.00 |
| Jun 30, 2024 | 41,715.00 |
| Mar 31, 2024 | 25,442.00 |
| Mar 31, 2024 | 25,442.00 |
| Dec 31, 2023 | 55,000.00 |
| Dec 31, 2023 | 55,000.00 |
| Sep 30, 2023 | 37,675.00 |
| Sep 30, 2023 | 37,675.00 |
| Jun 30, 2023 | 3,375.00 |
| Jun 30, 2023 | 3,375.00 |